Patient ownership of primary biliary cholangitis long-term management.
autoimmune liver disease
primary biliary cirrhosis
Journal
Frontline gastroenterology
ISSN: 2041-4137
Titre abrégé: Frontline Gastroenterol
Pays: England
ID NLM: 101528589
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
11
2019
revised:
02
03
2020
accepted:
30
04
2020
entrez:
11
4
2022
pubmed:
1
6
2020
medline:
1
6
2020
Statut:
epublish
Résumé
Patient ownership of disease is vital in rare diseases like primary biliary cholangitis (PBC). This survey of UK members of the PBC foundation aimed to assess patients' perception of their disease management, focusing on key biomarkers and problematic symptoms. Registered PBC foundation members were surveyed on their experiences on their most recent clinic visit, covering the type of hospital and clinician and whether biochemical response and symptom burden were discussed, including who initiated these conversations. Respondents were also asked about their willingness to initiate these conversations. Across 633 respondents, 42% remembered discussing alkaline phosphatase, the key biochemical response measure, and the majority of discussions were initiated by the healthcare provider. 56% of respondents remembered discussing itch, a key PBC symptom. There was no distinction between the grade of healthcare professional, but both patients and clinicians were significantly more likely to discuss symptoms over disease progression. Reassuringly, 84% of respondents felt willing to initiate conversations about their illness, regardless of the grade of managing clinician. This work lays a positive foundation for patient education and empowerment projects, likely to improve clinical outcomes. Key aspects of management (biochemical response to treatment and symptom burden) should be emphasised as topics of discussion to both patients and clinicians managing PBC. We suggest a simple cue card to prompt patient-led discussion.
Identifiants
pubmed: 35401960
doi: 10.1136/flgastro-2019-101324
pii: flgastro-2019-101324
pmc: PMC8989000
doi:
Types de publication
Journal Article
Langues
eng
Pagination
370-373Informations de copyright
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Lancet Gastroenterol Hepatol. 2018 Sep;3(9):626-634
pubmed: 30017646
Dig Dis Sci. 2018 Oct;63(10):2547-2554
pubmed: 29736833
Gastroenterology. 2013 Mar;144(3):560-569.e7; quiz e13-4
pubmed: 23246637
N Engl J Med. 2016 Aug 18;375(7):631-43
pubmed: 27532829
Ann Intern Med. 2005 Sep 20;143(6):427-38
pubmed: 16172441
Clin Gastroenterol Hepatol. 2019 Jun;17(7):1379-1387.e3
pubmed: 30557739